OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients

Joel D Kopple, Alfred K Cheung, Jens Sandahl Christiansen, Christian Born Djurhuus, Meguid El Nahas, Bo Feldt-Rasmussen, William E Mitch, Christoph Wanner, Marie Göthberg, Talat Alp Ikizler

    32 Citationer (Scopus)

    Abstrakt

    Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY™ Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.
    OriginalsprogEngelsk
    TidsskriftNephrology, Dialysis, Transplantation
    Vol/bind26
    Udgave nummer12
    Sider (fra-til)4095-103
    Antal sider9
    ISSN0931-0509
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients'. Sammen danner de et unikt fingeraftryk.

    Citationsformater